GENEOSCOPY

Revolutionizing colorectal cancer screening

The Problem

Colorectal cancer is the 2nd leading cause of cancer-related deaths, resulting in over 50,000 deaths annually. Existing screening tests are highly problematic and fail to meet the needs of patients. Invasive options, such as colonoscopies, are uncomfortable, time consuming, and expensive. On the other hand, noninvasive alternatives are unreliable due to low accuracy rates. Patients require a single screening test that can eliminate the time and discomfort associated with colonoscopies, improve the accuracy of testing, and reduce costs.

Metastatic, or stage IV colon cancers, have a 5-year relative survival rate of about 11%.”

– American Cancer Society

The Solution

Geneoscopy has developed a method to isolate and preserve biomarkers in stool samples. Geneoscopy is using these biomarkers, along with a customized detection algorithm, to provide patients with a noninvasive screening test that can accurately diagnose and treat colorectal cancer.

Noninvasive Procedure

Improved Patient Compliance

Low Cost

Heightened Care

Overall, the lifetime risk of developing colorectal cancer is: about 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for women

– American Cancer Society

Our Team

Erica Barnell

Chief Executive Officer

Erica Barnell graduated from Cornell University in 2013 with a dual degree in Biological Sciences and Applied Economics & Management. She started her career as a research technician at the Donald Danforth Plant Science Center in St. Louis, where she was engineering the staple food crop in Africa to be more nutritious. She then began working at Washington University School of Medicine to develop a noninvasive diagnostic test to evaluate children in Africa with Environmental Enteropathy. Currently, she is in her third year of the MD/PhD Program at the Washington University School of Medicine where her MD concentration is undecided and her PhD concentration is in Genetics and Genomics.

Andrew Barnell

Chief Financial Officer

Andrew began his career as a financial analyst in J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions in the biotech, medical devices and life science tools sectors. Subsequently, he worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on providing long-term growth capital to family owned businesses. As an undergraduate at Cornell University, Andrew studied Applied Economics & Management with a specialization in finance. He is currently receiving his MBA at The Wharton School, majoring in Health Care Management and Entrepreneurial Management.

Yiming Kang

Chief Technology Officer

Yiming is interested in data mining and genome analysis. He was as a biomedical engineer by training, who developed analysis tools to automatically extract features from medical imaging data. After receiving his Bachelor’s from University of Utah and Master’s from Cornell University, Yiming shifted his academic focus to genome science. His research has mainly been concentrated on machine learning approaches to tackle genomic network topics at Center for Genome Sciences & Systems Biology. He is pursuing a PhD degree in Computer Science at Washington University.



Contact Us

Geneoscopy, LLC

20 South Sarah Street
Saint Louis, MO 63108

geneoscopy@gmail.com